Rienso® (ferumoxytol) receives European marketing authorisation for the treatment of iron deficiency anaemia in adult chronic kidney disease patients


London, United Kingdom and Lexington, MA, USA, June 22, 2012, and Osaka, Japan, June 25, 2012 – Takeda Pharmaceutical Company Limited (Takeda) and AMAG Pharmaceuticals, Inc. today announced the granting of marketing authorisation by the European Commission (EC) for ferumoxytol, a new intravenous (IV) iron therapy to treat iron deficiency anaemia (IDA) in adult patients with chronic kidney disease (CKD). The marketing authorisation follows a positive opinion issued on April 19, 2012, by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). With receipt of the EC decision, Takeda intends to launch ferumoxytol across Europe in the near future.

Read more


Top of page

Takeda Pharma